Your browser is no longer supported. Please, upgrade your browser.
Baudax Bio, Inc.
Index- P/E- EPS (ttm)-5.85 Insider Own1.10% Shs Outstand42.64M Perf Week18.94%
Market Cap68.48M Forward P/E- EPS next Y-0.76 Insider Trans0.00% Shs Float25.91M Perf Month61.03%
Income-66.40M PEG- EPS next Q-0.59 Inst Own16.50% Short Float5.38% Perf Quarter-0.63%
Sales0.40M P/S171.21 EPS this Y57.10% Inst Trans-0.01% Short Ratio0.40 Perf Half Y-54.49%
Book/sh-2.46 P/B- EPS next Y81.70% ROA-100.10% Target Price- Perf Year-81.59%
Cash/sh0.56 P/C2.78 EPS next 5Y- ROE168.90% 52W Range0.97 - 10.14 Perf YTD55.45%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-84.52% Beta-
Dividend %- Quick Ratio1.40 Sales past 5Y- Gross Margin- 52W Low61.86% ATR0.13
Employees24 Current Ratio1.50 Sales Q/Q- Oper. Margin- RSI (14)68.61 Volatility15.63% 9.02%
OptionableYes Debt/Eq- EPS Q/Q154.80% Profit Margin- Rel Volume3.16 Prev Close1.70
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume3.52M Price1.57
Recom1.70 SMA2034.29% SMA5039.11% SMA200-40.23% Volume10,858,940 Change-7.65%
May-15-20Initiated JMP Securities Mkt Outperform $13
Jan-21-21 09:29AM  
Jan-06-21 07:00AM  
Dec-17-20 07:00AM  
Dec-08-20 08:40AM  
Dec-07-20 05:17PM  
Nov-30-20 04:05PM  
Nov-23-20 08:00AM  
Nov-20-20 07:00AM  
Nov-19-20 07:00AM  
Nov-11-20 05:30AM  
Nov-09-20 07:15AM  
Nov-02-20 07:05AM  
Oct-20-20 07:00AM  
Oct-02-20 04:05PM  
Sep-18-20 07:35AM  
Sep-01-20 03:30PM  
Aug-25-20 04:05PM  
Aug-20-20 05:57PM  
Aug-17-20 12:28PM  
Aug-10-20 07:15AM  
Aug-06-20 04:05PM  
Jul-30-20 04:05PM  
Jul-20-20 07:00AM  
Jul-05-20 02:53PM  
Jul-03-20 03:25PM  
Jun-15-20 07:00AM  
Jun-01-20 07:00AM  
May-18-20 06:12AM  
May-08-20 07:00AM  
May-05-20 07:00AM  
May-01-20 04:05PM  
Apr-29-20 10:02AM  
Apr-23-20 07:00AM  
Apr-07-20 08:00AM  
Apr-03-20 06:40PM  
Mar-26-20 11:35AM  
Mar-24-20 09:15AM  
Mar-23-20 04:20PM  
Mar-04-20 11:43AM  
Feb-20-20 04:05PM  
Feb-19-20 06:16PM  
Feb-13-20 04:08PM  
Jan-22-20 07:00AM  
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHURCHILL WINSTON JDirectorMar 26Buy2.286,50014,8206,500Mar 30 08:00 PM
CHURCHILL WINSTON JDirectorMar 26Buy2.4425,00061,00052,782Mar 30 08:00 PM
Weisman WayneDirectorMar 26Buy2.2910,00022,90040,582Mar 27 03:53 PM
ALTOMARI ALFREDDirectorMar 26Buy2.345,00011,70033,382Mar 27 03:51 PM